Thrombolytic agents have been demonstrated to improve free flap salvage in
animal models. However, clinical evidence regarding their efficacy has been
scant. The authors reviewed their experience with flap salvage using throm
bolytic therapy in 1,733 free flaps from February 1990 to July 1998. Patien
ts with intraoperative pedicle thrombosis were excluded from this review. F
orty-one of the 55 free flaps that were reexplored emergently were identifi
ed as having pedicle thrombosis. Of these 41 flaps, 28 free flaps were salv
aged (flap salvage group, 68%) and 13 free flaps failed (flap failure group
, 32%). Thrombolytic therapy (urokinase in 7 patients, tissue plasminogen a
ctivator in I patient) was used in six flaps in the flap salvage group and
two flaps in the flap failure group. Statistical analysis demonstrated no d
ifference between the two groups with regard to thrombolytic therapy. There
was also no difference between the two groups with regard to use of system
ic heparin (100-500 U per hour) at the time of pedicle thrombosis or with r
egard to whether Fogarty catheters were used. Smoking, preoperative radioth
erapy, and the use of interpositional vein grafts during initial flap recon
struction had no impact on the outcome of flap salvage. The flap salvage gr
oup was reexplored at a mean of 1.5 days compared with the flap failure gro
up, which was reexplored at a mean of 4.2 days (p = 0.007). Early detection
of pedicle thrombosis remains the most important factor in the salvage of
free flaps. Although these numbers are small and definitive statements' can
not be made, the role of thrombolytic agents in free flap salvage requires
further clinical evaluation.